USD 9.08
(-3.55%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | - USD | 0.0% |
2022 | - USD | 0.0% |
2021 | - USD | 0.0% |
2020 | - USD | 0.0% |
2019 | - USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 100.0% |
2016 | -1252.00 USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 100.0% |
2013 | -12 Thousand USD | 0.0% |
2012 | - USD | 100.0% |
2011 | -63.11 Thousand USD | -392.66% |
2010 | -12.81 Thousand USD | 0.0% |
2009 | - USD | 100.0% |
2008 | -75 Thousand USD | -7.14% |
2007 | -70 Thousand USD | -9233.33% |
2006 | -750.00 USD | 75.0% |
2005 | -3000.00 USD | 0.0% |
2004 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | - USD | 0.0% |
2024 Q1 | - USD | 0.0% |
2024 Q3 | - USD | 0.0% |
2023 Q3 | - USD | 0.0% |
2023 FY | - USD | 0.0% |
2023 Q2 | - USD | 0.0% |
2023 Q1 | - USD | 0.0% |
2023 Q4 | - USD | 0.0% |
2022 Q3 | - USD | 0.0% |
2022 Q1 | - USD | 0.0% |
2022 FY | - USD | 0.0% |
2022 Q4 | - USD | 0.0% |
2022 Q2 | - USD | 0.0% |
2021 Q3 | - USD | 0.0% |
2021 Q4 | - USD | 0.0% |
2021 FY | - USD | 0.0% |
2021 Q1 | - USD | 0.0% |
2021 Q2 | - USD | 0.0% |
2020 Q2 | - USD | 0.0% |
2020 FY | - USD | 0.0% |
2020 Q3 | - USD | 0.0% |
2020 Q4 | - USD | 0.0% |
2020 Q1 | - USD | 0.0% |
2019 Q2 | - USD | 0.0% |
2019 FY | - USD | 0.0% |
2019 Q1 | - USD | 0.0% |
2019 Q3 | - USD | 0.0% |
2019 Q4 | - USD | 0.0% |
2018 Q4 | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 FY | - USD | 100.0% |
2017 Q3 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 FY | -1252.00 USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2014 Q2 | - USD | 100.0% |
2014 FY | - USD | 100.0% |
2014 Q1 | -12 Thousand USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | -12 Thousand USD | 0.0% |
2013 Q4 | -12 Thousand USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 100.0% |
2012 Q2 | - USD | 0.0% |
2012 Q1 | - USD | 100.0% |
2011 Q3 | - USD | 100.0% |
2011 Q1 | -41.81 Thousand USD | -226.46% |
2011 FY | -63.11 Thousand USD | -392.66% |
2011 Q4 | -63.11 Thousand USD | 0.0% |
2011 Q2 | -10.99 Thousand USD | 73.7% |
2010 FY | -12.81 Thousand USD | 0.0% |
2010 Q4 | -12.81 Thousand USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2010 Q1 | - USD | 0.0% |
2009 Q1 | - USD | 100.0% |
2009 Q2 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 FY | - USD | 100.0% |
2008 Q3 | - USD | 100.0% |
2008 Q2 | -30 Thousand USD | 0.0% |
2008 FY | -75 Thousand USD | -7.14% |
2008 Q1 | -30 Thousand USD | 57.14% |
2008 Q4 | -75 Thousand USD | 0.0% |
2007 Q3 | - USD | 100.0% |
2007 FY | -70 Thousand USD | -9233.33% |
2007 Q2 | -10 Thousand USD | 0.0% |
2007 Q4 | -70 Thousand USD | 0.0% |
2007 Q1 | - USD | 100.0% |
2006 Q3 | - USD | 0.0% |
2006 Q4 | -750.00 USD | 0.0% |
2006 FY | -750.00 USD | 75.0% |
2006 Q1 | -750.00 USD | 75.0% |
2006 Q2 | - USD | 100.0% |
2005 FY | -3000.00 USD | 0.0% |
2005 Q3 | - USD | 0.0% |
2005 Q2 | - USD | 0.0% |
2005 Q4 | -3000.00 USD | 0.0% |
2005 Q1 | - USD | 0.0% |
2004 FY | - USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Editas Medicine, Inc. | -99.52 Million USD | 100.0% |
Dynavax Technologies Corporation | 182.11 Million USD | 100.0% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 100.0% |
Perrigo Company plc | 1.68 Billion USD | 100.0% |
Illumina, Inc. | 2.74 Billion USD | 100.0% |
Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.0% |
Iovance Biotherapeutics, Inc. | -9.56 Million USD | 100.0% |
Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.0% |
IQVIA Holdings Inc. | 5.23 Billion USD | 100.0% |
Heron Therapeutics, Inc. | 10.04 Million USD | 100.0% |
Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.0% |
Unity Biotechnology, Inc. | -19.69 Million USD | 100.0% |
Waters Corporation | 1.76 Billion USD | 100.0% |
Biogen Inc. | 7.3 Billion USD | 100.0% |
Sangamo Therapeutics, Inc. | -45.32 Million USD | 100.0% |
Evolus, Inc. | 140.52 Million USD | 100.0% |
Adicet Bio, Inc. | -6.09 Million USD | 100.0% |
Cara Therapeutics, Inc. | 14.79 Million USD | 100.0% |
bluebird bio, Inc. | -4.03 Million USD | 100.0% |
Esperion Therapeutics, Inc. | 73.06 Million USD | 100.0% |
FibroGen, Inc. | 128.9 Million USD | 100.0% |
Agilent Technologies, Inc. | 3.46 Billion USD | 100.0% |
Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 100.0% |
Homology Medicines, Inc. | -7.22 Million USD | 100.0% |
Geron Corporation | -123.5 Million USD | 100.0% |
Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 100.0% |
Amicus Therapeutics, Inc. | 362.03 Million USD | 100.0% |
Myriad Genetics, Inc. | 476.4 Million USD | 100.0% |
Viking Therapeutics, Inc. | -292 Thousand USD | 100.0% |
Intellia Therapeutics, Inc. | -398.79 Million USD | 100.0% |
Zoetis Inc. | 5.83 Billion USD | 100.0% |
Abeona Therapeutics Inc. | 302 Thousand USD | 100.0% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 100.0% |
BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 100.0% |
Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.0% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 100.0% |
Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 100.0% |
Atara Biotherapeutics, Inc. | -313 Thousand USD | 100.0% |
Verastem, Inc. | -62 Thousand USD | 100.0% |
Nektar Therapeutics | 53.47 Million USD | 100.0% |
Axsome Therapeutics, Inc. | 244.53 Million USD | 100.0% |
Aclaris Therapeutics, Inc. | -85.21 Million USD | 100.0% |
Sarepta Therapeutics, Inc. | 1.09 Billion USD | 100.0% |
OPKO Health, Inc. | 318.12 Million USD | 100.0% |
Exelixis, Inc. | 1.75 Billion USD | 100.0% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 100.0% |
Corcept Therapeutics Incorporated | 475.89 Million USD | 100.0% |
uniQure N.V. | 2.21 Million USD | 100.0% |
Imunon, Inc. | -720 Thousand USD | 100.0% |
Blueprint Medicines Corporation | 236.58 Million USD | 100.0% |
Insmed Incorporated | 239.63 Million USD | 100.0% |
Halozyme Therapeutics, Inc. | 636.89 Million USD | 100.0% |
Agios Pharmaceuticals, Inc. | 17.31 Million USD | 100.0% |
TG Therapeutics, Inc. | 219.1 Million USD | 100.0% |
Incyte Corporation | 3.44 Billion USD | 100.0% |
Emergent BioSolutions Inc. | 343.9 Million USD | 100.0% |